Global Blood Therapeutics buoyed by good news from FDA; Cigna to help cover pricey therapies
→ Global Blood Therapeutics $GBT has much to cheer about. Not only has the FDA granted its sickle cell disease (SCD) drug priority review …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
